Table 1.
Baseline characteristics of study patients (n = 89)
| Characteristics | Different status of HBV infection | P Value | ||
|---|---|---|---|---|
| CHB n(%) | RHB n(%) | HBV n(%) | ||
| Total | 13 | 49 | 27 | |
| Age (years) | 0.936 | |||
| ≤60 | 6(46.2) | 20(40.8) | 11(40.7) | |
| ＞60 | 7(53.8) | 29(59.2) | 16(59.3) | |
| Sex | 0.284 | |||
| Male | 11(84.6) | 30(61.2) | 18(66.7) | |
| Female | 2(15.4) | 19(38.8) | 9(33.3) | |
| BMI（kg/m2） | 0.082 | |||
| BMI ≥ 24 | 2(15.4) | 13(26.5) | 5(18.5) | |
| 18.5 ≤ BMI < 24 | 8(61.5) | 19(38.8) | 19(70.4) | |
| BMI < 18.5 | 3(23.1) | 17(34.7) | 3(11.1) | |
| Smoking status | 0.871 | |||
| Current or former | 2(15.4) | 5(10.2) | 3(11.1) | |
| Never | 11(84.6) | 44(89.8) | 24(88.9) | |
| Comorbidity of Hepatitis C | / | |||
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| No | 13(100.0) | 49(100.0) | 27(100.0) | |
| Pathological type | 0.656 | |||
| Adenocarcinoma | 12(92.3) | 41(83.7) | 24(88.9) | |
| Other | 1(7.7) | 8(16.3) | 3(11.1) | |
| Lines of immunotherapy | 0.377 | |||
| First-line | 10(76.9) | 37(75.6) | 20(74.1) | |
| Second-line | 1(7.7) | 5(10.2) | 6(22.2) | |
| Back-line | 2(15.4) | 7(14.2) | 1(3.7) | |
| Combined chemotherapy | 0.854 | |||
| Yes | 12(92.3) | 46(93.9) | 26(96.3) | |
| No | 1(7.7) | 3(6.1) | 1(3.7) | |
| Baseline HBV-DNA | 0.106 | |||
| Detectable | 11(84.6) | 28(57.1) | / | |
| Unknown | 2(15.4) | 21(42.9) | / | |
| PD-L1 | 0.096 | |||
| Detectable | 3(23.1) | 27(55.1) | 11(40.7) | |
| Unknown | 10(76.9) | 22(44.9) | 16(59.3) | |
| PD-1 inhibitor type | 0.577 | |||
| Nivolumab | 2(15.4) | 8(16.3) | 2(7.4) | |
| Sintilimab | 9(69.2) | 38(77.6) | 21(77.8) | |
| Others | 2(15.4) | 3(6.1) | 4(14.8) | |
HBV hepatitis B virus, CHB chronic hepatitis B virus infection, RHB resolved hepatitis B virus infection, HBV- HBV uninfected, HBV-DNA HBV deoxyribonucleic acid, BMI Body Mass Index, PD-(L)1 programmed death (ligand) 1